Abstracts

Citation

Aditya H. Gaur, Kristin Baltrusaitis, Edmund V. Capparelli, John H. Moye, Dwight E. Yin, Avy Violari, Barbara Heckman, Sarah Buisson, Rodica M. Van Solingen-Ristea, Conn M. Harrington, Mark A. Marzinke, Elizabeth D. Lowenthal, Shawn Ward, Ryan Milligan, Brookie M. Best, Ellen Townley, Allison L. Agwu, Cynthia McCoig, Jenny Huang, Gilly Roberts, Herta Crauwels, Veerle Van Eygen, Chelsea Krotje, Sara Zabih, Gaerolwe Masheto, Pradthana Ounchanum, Linda Aurpibul, Violet Korutaro, Carolyn Bolton Moore. LONG-ACTING CABOTEGRAVIR (CAB) PLUS RILPIVIRINE (RPV) IN THE FIRST, VIROLOGICALLY-SUPPRESSED ADOLESCENTS WITH HIV-1 TO RECEIVE AN EVERY 8-WEEK, ALL-INJECTABLE REGIMEN IN A MULTICENTER, MULTINATIONAL STUDY: IMPAACT 2017 WEEK 48 OUTCOMES. Presented at: International AIDS Conference; 2024 Jul 22.

Citation

Aditya Gaur, Edmund Capparelli, Kristin Baltrusaitis, Mark Marzinke, Conn Harrington, Cindy McCoig, Herta Crauwels, Ellen Townley, John Moye, Sarah Buisson, Avy Violari, Pradthana Ounchanum, Chelsea Krotje, Carolyn Bolton Moore, IMPAACT 2017 Team. LONG-ACTING CABOTEGRAVIR PLUS RILPIVIRINE IN ADOLESCENTS WITH HIV: WEEK 24 IMPAACT 2017 STUDY. Presented at: CROI 2024.

Citation

Aditya Gaur, Kristin Baltrusaitis, Edmund Capparelli, Elizabeth Lowenthal, Mark Marzinke, Herta Crauwels, Amy Cheung, Ellen Townley, John Moye, Michael Whitton, Gaerolwe Masheto, Sisinyana Ruth Mathiba, Barbara Heckman, Carolyn Bolton Moore, IMPAACT 2017 Team. Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End of Study Results. Presented at: CROI 2026; 2026 Feb 24.

Citation

Long-distance mentorship program to build capacity of new investigators from resource-limited settings in HIV research. Presented at: 2nd International Workshop on HIV Pediatrics.

Citation

Long-Term (72 Weeks) Immunogenicity and Increased Response Rates After a Second Dose of Quadrivalent Meningococcal Conjugate Vaccine in HIV-Infected Children and Youth. Presented at: 18th Conference on Retroviruses & Opportunistic Infections.

Citation

Kunjal Patel, D.Sc., M.P.H., Miguel A. Hernan, Paige L. Williams, Ph.D., John D. Seeger, Kenneth McIntosh, M.D., George Seage, III, Sc.D., M.P.H. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents infected with HIV-1. Presented at: XVI International AIDS Conference.

Citation

K Patel, J Lindsey, M Hernan, K Angelidou, G Aldrovandi, P Palumbo for the IMPAACT P1060 Study Team. Long-term metabolic implications of initiating lopinavir/ritonavir-based regimens for infants and children: a follow-up study of IMPAACT P1060. Presented at: IAS 2017.

Citation

Linda Barlow-Mosha, Konstantia Angelidou, Moherndran Archary, Avy Violari, Jane Lindsey, Lynne Mofenson, Patrick Jean-Philippe, Paul Palumbo, Benjamin Chi, on behalf of the P1060 protocol team. Long-Term Outcomes of HIV-Infected Children Initiating NVP vs, LPV/R Based Treatment. Presented at: CROI 2015; 2015 Feb 25.

Citation

Edmund Capparelli, Pharm.D., Jorge Pinto, M.D., D.Sc., Brian Robbins, Ph.D., Carmelita Alvero, Ram Yogev, M.D., Paul Palumbo, M.D., John H. Rodman, Pharm.D., Barbara E. Heckman, B.S., Ellen Gould Chadwick, M.D. Lopinavir pharmacokinetic (PK) maturational changes and variability in HIV-infected infants beginning Kaletra (LPV/r) therapy at < 6 weeks (WK) of age. Presented at: 15th Conference on Retroviruses & Opportunistic Infections.

Citation

M Nikanjam, Edmund Capparelli, Pharm.D., Brian Robbins, Ph.D., Jorge Pinto, M.D., D.Sc., Ram Yogev, M.D., Carmelita Alvero, Paul Palumbo, M.D., Michael Hughes, Ph.D., John H. Rodman, Pharm.D., Ellen Gould Chadwick, M.D. Lopinavir population pharmacokinetic model and dose simulation predicts rapid increase in exposure for HIV-infected infants initiating therapy at <6 months of age (IMPAACT/PACTG P1030). Presented at: 16th Conference on Retroviruses & Opportunistic Infections.